The influence of nicotinic hepatic metabolism on neuroreceptor substrates of nicotine addiction

The influence of nicotinic hepatic metabolism on neuroreceptor substrates of nicotine addiction
Recruiting
18 years - 99 years
All
Phase 1
30 participants needed
1 Location

Brief description of study

We will examine differences in nAChR availability based on individual differences in the nicotine metabolism rate. Work conducted by Dr. Lermans group at Penn, in collaboration with Drs. Rachel Tyndale (University of Toronto) and Neal Benowitz (University of California, San Francisco) has documented differences in smoking cessation and treatment response between slow and normal metabolizers of nicotine. Nicotine is metabolized primarily by the CYP2A6 enzyme to the inactive metabolites cotinine and 3-hydroxycotinine. The ratio of 3-hydroxycotinine to cotinine, referred to as the nicotine metabolite ratio (NMR), is a reproducible measure of CYP2A6 activity that accounts for other genetic and environmental influences on nicotine clearance (e.g., hormonal factors). This biomarker is strongly correlated with nicotine clearance and CYP2A6 genotype amongst smokers of both European and African descent. Slower metabolizers (i.e., those in the lowest quartile of the NMR) have higher quit rates with nicotine patch or placebo treatment than normal metabolizers (i.e., 2nd to 3rd quartiles) and fast metabolizers (i.e., 4th quartile). In our initial study, we found that slower metabolizers demonstrated decreased nAChR availability following overnight abstinence 1. The effects of the NMR on quitting success are greater than the effects of other clinical measures (e.g., the severity of nicotine dependence), such that NMR is the strongest genetically-informed biomarker of smoking cessation. Differences in brain receptor levels secondary to differing durations of nicotine present in the brains of slow versus fast nicotine metabolizers is hypothesized to account for the effects of the NMR on quitting success. We will test this hypothesis by examining the association of variation in nicotine metabolism with differences in brain nAChR availability overnight as well as after two days of nicotine abstinence.

Detailed description of study

Adult smokers will undergo two research PET/CT imaging scans using an experimental tracer called 2-18F-FA. One scan visit after 1 day of not smoking will include an 8 hour long infusion, which includes 2 hours of scan time. The second scan visit after 2 days of not smoking will include the same 8 hour infusion, including 2 hours of scan time. The second visit will also include an overnight stay at the hospital the day before the scan visit. Subjects may also have a brain MRI.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Smoking
  • Age: 18 years - 99 years
  • Gender: All
Updated on 19 Feb 2024. Study ID: 828090

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.